Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a hematologic malignancy that has seen significant advances in care over the last 5 years with the approval of oral agents such as ibrutinib and venetoclax for the treatment of this disease. As such, there has been a substantial shift away from the traditional c...

Full description

Bibliographic Details
Published in:	Pharmacy
Main Authors:	Kevin Y. Chen, Kelly M. Brunk, Bianka A. Patel, Kurtis J. Stocker, Jessica J. Auten, Kaitlyn M. Buhlinger, Benyam Muluneh
Format:	Article
Language:	English
Published:	MDPI AG 2020-03-01
Subjects:	CLL pharmacist ibrutinib venetoclax initiation toxicity
Online Access:	https://www.mdpi.com/2226-4787/8/2/52

Similar Items

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
by: Elizabeth M. Muhowski, et al.
Published: (2022-11-01)

SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01)

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia
by: Daphne Guinn, et al.
Published: (2017-04-01)

State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
by: Richard Lemal, et al.
Published: (2019-08-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
by: Natalia Timofeeva, et al.
Published: (2023-05-01)

Search for Synergistic Drug Combinations to Treat Chronic Lymphocytic Leukemia
by: Eleonora Ela Hezkiy, et al.
Published: (2022-11-01)

Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib
by: Baustin M. Welch, et al.
Published: (2023-12-01)

Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment
by: Otašević Vladimir, et al.
Published: (2019-01-01)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
by: Keisuke Kidoguchi, et al.
Published: (2021-02-01)

Pneumonia in patients with chronic lymphocytic leukemia treated with venetoclax‐based regimens: A real‐world analysis of Polish Adult Leukemia Group (PALG)
by: Elżbieta Kalicińska, et al.
Published: (2025-02-01)

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia
by: Benjamin Heyman, et al.
Published: (2025-08-01)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
by: Francesco Angotzi, et al.
Published: (2022-02-01)

MODERN APPROACHES TO TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
by: A. A. Danilenko, et al.
Published: (2020-12-01)

Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01)

RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?
by: Antonio Cuneo, et al.
Published: (2019-02-01)

An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib
by: Fady Gh Haddad, et al.
Published: (2021-01-01)

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs
by: Lindsey Fitzgerald, et al.
Published: (2025-10-01)

Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment
by: A. V. Rudakova, et al.
Published: (2020-04-01)

Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System
by: Christopher Lemieux, et al.
Published: (2025-09-01)

The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
by: Alexandria P. Eiken, et al.
Published: (2024-08-01)

Management of infections for patient treated with ibrutinib in clinical practice
by: Claudia Baratè, et al.
Published: (2024-09-01)

Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
by: Elżbieta Iskierka-Jażdżewska, et al.
Published: (2025-01-01)

Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region
by: Mohamed A. Yassin, et al.
Published: (2025-02-01)

Effects of ibrutinib and venetoclax on the expression of immune checkpoint molecules in leukemic blasts of patients with acute lymphoblastic leukemia
by: Armin Dozandeh-Jouybari, et al.
Published: (2025-06-01)

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells
by: Fengbo Jin, et al.
Published: (2024-10-01)

Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time‐limited venetoclax/obinutuzumab treatment
by: Maria Dimou, et al.
Published: (2021-07-01)

Possibilities of therapy recurrent b-cell chronic lymphocytic leukemia associated with autoimmune complications: data from literature and personal observation
by: S. R. Goryacheva, et al.
Published: (2018-07-01)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
by: Anthony Mato, et al.
Published: (2023-02-01)

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01)

Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications
by: Wojciech Szlasa, et al.
Published: (2025-06-01)

Bcl-2 inhibition in the treatment of hematologic malignancies
by: John X. Wei, et al.
Published: (2023-12-01)

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
by: Tambaro FP, et al.
Published: (2021-10-01)

Frontline therapies for untreated chronic lymphoid leukemia
by: Delong Liu, et al.
Published: (2019-08-01)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
by: Xue Yi, et al.
Published: (2022-02-01)

Quantitative Assessment of Red Blood Cell Disaggregation in Chronic Lymphocytic Leukemia via Software Image Flow Analysis
by: Anika Alexandrova-Watanabe, et al.
Published: (2025-06-01)

Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1
by: Stefania Fiorcari, et al.
Published: (2022-01-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
by: Ana-Maria Moldovianu, et al.
Published: (2023-02-01)

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
by: Valeria J. Sarapura Martinez, et al.
Published: (2023-03-01)